<DOC>
	<DOCNO>NCT01569152</DOCNO>
	<brief_summary>The purpose study assess safety efficacy MK-8457 + Methotrexate ( MTX ) participant active rheumatoid arthritis ( RA ) despite MTX therapy . The primary hypothesis least 1 dose MK-8457 + MTX superior placebo + MTX measure percentage participant achieve American College Rheumatology 20 ( ACR 20 ) response 12 week treatment .</brief_summary>
	<brief_title>Safety Efficacy MK-8457 Methotrexate ( MTX ) Participants With Active Rheumatoid Arthritis Despite MTX Therapy ( P08683 , MK-8457-008 )</brief_title>
	<detailed_description>In Base Study Phase IIa , participant receive blind MK-8457 100 mg match placebo 24 week . At Week 12 18 Phase IIa , efficacy evaluation conduct assess eligibility early escape , define &lt; 20 % reduction tender swell joint count . The study plan include Base Study Phase IIb dose range find dose-response evaluate , depend outcome Phase IIa . Participants complete Phase IIa Phase IIb eligible early escape could enroll Period 3 , 2-year Safety Extension . All participant must treat MTX least 3 month prior screen receive stable dose MTX least 4 week prior screen .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosis rheumatoid arthritis least 6 month prior screen Active rheumatoid arthritis define presence &gt; = 6 swollen joint ( 66 count ) &gt; = 6 tender joint ( 68 joint count ) Creactive protein blood level &gt; 0.9 mg/dL Anticitrullinated protein antibody positive and/or rheumatoid factor positive screening American College Rheumatology Functional Class I , II , III Received methotrexate minimum 3 month prior screen regionally appropriate stable weekly dose least 4 week prior screen If use oral corticosteroid , participant must stable dose 10 mg prednisone No history either untreated , latent , active tuberculosis prior baseline Participants reproductive potential must agree remain abstinent use 2 acceptable method birth control Presence inflammatory disease rheumatoid arthritis , include limited psoriatic arthritis , ankylose spondylitis , systemic lupus erythematosus , Lyme disease Positive hepatitis B surface antigen hepatitis C test result presence Human immunodeficiency virus ( HIV ) infection HIV positive User recreational illicit drug history ( within previous 2 year ) drug alcohol abuse dependence Females childbearing potential pregnant , intend become pregnant , lactate ; Severe opportunistic infection within 6 month prior study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>